ALR Technologies Announces Patent Grant for Predictive A1C and Successful Results from Singapore General Hospital-led Study
ALR Technologies SG Ltd. (“ALRT” or the “Company”) (OTCQB: ALRTF), a diabetes management company, announces the patent application titled Method and System of Monitoring a Diabetes Treatment Plan (“Predictive A1c”) has been granted in Singapore and has received notice of…
Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with drugs containing fluorouracil and platinum for the…
Arjuna Natural’s Turmeric–Frankincense Botanical Blend Relieves Menstrual Pain in Clinical Study
Kerala, India – A novel botanical formula powered by turmeric (Curcuma longa L), and frankincense (Boswellia serrata) has demonstrated abilities to alleviate menstrual cramps in a new clinical study. Rhuleave-K®, a breakthrough blend composed by the renowned nutraceutical company Arjuna…
Hansa Biopharma Reaches a Crucial Milestone in Imlifidase Phase 2 Clinical Trial for Guillain-Barré Syndrome
Hansa Biopharma (Nasdaq Stockholm: HNSA), a trailblazer in the world of enzyme technology aimed at rare immunological conditions, proudly announces that enrollment for its phase 2 clinical trial of imlifidase in Guillain-Barré Syndrome (GBS) has been successfully completed. The study’s…
Glenmark’s innovative immune-oncology drug for advanced solid tumors and lymphomas receives FDA acceptance for Phase 1/2 clinical study
Glenmark Pharmaceuticals Ltd.’s subsidiary, Glenmark Specialty SA, has achieved a breakthrough in the fight against advanced solid tumors and lymphomas. The US Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for GRC 54276, an…
